retatrutide type 2 diabetes phase 2 results 2024 ada 💉 A triple-action once-weekly injection can significantly lower blood sugar and body weight in people with diabetes, a new 3 trial shows. is part of an emerging generation Lilly's triple agonist achieves 16.8%

For researchers tracking this space, the key trials to watch in 2026 include the remaining TRIUMPH program readouts for retatrutide, the GLORY-OSA trial for mazdutide in obstructive sleep apnea, and the first Phase 1 data from several quadruple-agonist programs entering clinical development

As of April 2026, two trials have read out and seven more are expected to report through the year, with NDA filing targeted for Q4 2026

doi:10.1016/j.mce.2020.110835 174

Well also go over any important safety information, potential side effects, and provide guidance on nutrition, lifestyle, and ongoing support throughout your journey

PMID: 24217090

So even if a patch youve seen online has glowing reviews, those experiences may reflect a placebo effect